Kornimate/medical-research-clean huggingface dataset:
vapocoolant analgesia for breast lymphoscintigraphy

Conditions: Breast Cancer

Summary: to learn if applying vapocoolant anesthetic spray ("nüm") on the surface of the intended injection site will reduce the pain/anxiety associated with breast injections.

primary objectives: 1. establish feasibility of topical vapocoolant in the setting of breast lymphoscintigraphy. 2. demonstrate safety of topical vapocoolant in the setting of breast lymphoscintigraphy. secondary objectives: 1. to assess patient pain intensity associated with the performance of breast lymphoscintigraphy. 2. to evaluate the attitude from patients about supporting the continued offering of topical vapocoolant in the breast lymphoscintigraphy clinic.

Eligibility criteria:
inclusion criteria: * any adult patient undergoing asubareolar breast lymphoscintigraphy injection will be eligible. * age ≥18 years old * ability to understand and the willingness to sign a written informed consent document. * childbearing potential, lactating, pregnant women will be included. exclusion criteria: * patients who have allergy or had prior hypersensitivity to either of the vapocoolants including 1,1,1,3,3 pentafluoropropane and 1,1,1,2-tetrafluoroethane. * patients with uncontrolled intercurrent illness (insulin dependent and non-insulin dependent diabetes) * patients with psychiatric illness/social situations that would limit compliance with study requirements.
argatroban monitoring in critically ill patients: evaluation of a novel ecarin-based bedside test

Conditions: Heparin-induced Thrombocytopenia

Summary: argatroban is a parenteral direct thrombininhibitor used for anticoagulation in patients suffering from heparin induced thrombocytopenia (hit). there is increasing evidence suggesting that the activated partial thromboplastine time (aptt), which is recommended for dosage monitoring, correlates poorly with serum argatroban concentration in critically ill patients. therefore it may be badly suited to determine the correct dosing. ecarin based tests have been proven to be effective in determining effects of direct thrombin inhibitors. the investigators now plan to evaluate a novel, rotational thrombelastometric, ecarin based bedside test for its ability to measure the effect of argatroban in critically ill patients. so far an excellent correlation of a similar test could be shown in spiked plasma of healthy adults. according to the manufacturer the eca-test is able to detect direct thrombininhibitors. however to our knowledge neither the eca-test nor other ecarin-based thrombelastometric tests have been studied in critically ill patients treated with argatroban. the investigators therefore seek to investigate the correlation of the eca-test (clotpro®) with the serum argatroban concentration.


Eligibility criteria:
inclusion criteria: * continuous infusion of argatroban in routine clinical use according to local standard of care * expected length of stay at icu \> 4 days * 18 years exclusion criteria: * heparin infusion in the last fourhours

Keywords: argatroban eca-test ecarin clot-pro thrombelastometry rotem
outcomes of surgical treatment of patients with spinal metastasis in auh

Conditions: Spinal Metastases

Summary: to analyze the outcomes of surgical treatment of patients with spinal metastases in spine unit in auh regarding the pain control, neurological status and ambulatory status as well as survival rate .

this study monitor what is the results after operative treatment of patients which have secondary metastases in spinal column concerning quality of live for one year and pain and neurology

Eligibility criteria:
inclusion criteria: * patients \> 18 years old * patient with tissue proven dx of cancer exclusion criteria: * patient younger 18 years old * cns or spinal 1ry tumor
artificial intelligence - assisted model for optimal timing of surgery in advanced ovarian cancer

Conditions: Ovarian, Fallopian, and Primary Peritoneal Cancer; Artificial Intelligence (AI)

Summary: this study integrates data from the randomized controlled sunny trial (rct) and real-world (rwd) data, and employs multimodal data fitting to construct a medical artificial intelligence model to identify the clinical characteristics of patient subgroups suitable for primary debulking surgery (pds) or interval debulking surgery (ids), and the cutoff values for selecting different timings of surgery for advanced ovarian cancer.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients who were included in the sunny study or who were newly diagnosed with stage iiic or iv primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer during the sunny study period (2015-2023) * underwent primary debulking surgery or interval debulking surgery * data avaliable on first-line treatment and follow-up exclusion criteria: * non-epithelial ovarian cancer or borderline tumors. * low-grade tumors. * mucinous ovarian cancer. * missing data on first-line treatment and follow-up
survey on attitudes about covid-19 vaccinations in italian hcw

Conditions: Vaccination Hesitancy

Summary: the project is aimed at analyzing the perceptions, knowledge, attitudes and intentions of the population towards the anti-sars-cov-2 vaccine in order to identify the determinants of vaccine refusal/hesitancy, and to guide specific activities aimed at updating and the implementation of institutional communication strategies on the vaccine, involving health professionals and targeting the general population.


Eligibility criteria:
inclusion criteria: * healthcare workers residing in italy exclusion criteria: * healthcare workers not residing in italy
n-acetylcysteine and smoking reduction

Conditions: Nicotine Dependence

Summary: n-acetylcysteine is an inexpensive agent with a benign side effect profile with preliminary studies in humans suggesting efficacy for the treatment of cocaine dependence. n-acetylcysteine has been used in clinical medicine for nearly three decades to treat chronic lung conditions, acetaminophen overdose, and experimentally to treat cocaine dependence. it is generally safe and well tolerated. the present pilot study seeks to explore safety and tolerability, ad lib smoking, visual cue reactivity, and smoking reduction rates in a group of nontreatment seeking, nicotine dependence smokers who are willing to undergo a brief trial with oral n-acetylcysteine 1200 mg twice daily.


Eligibility criteria:
inclusion criteria: 1. be smokers motivated to reduce their cigarette usage but not seeking treatment to quit smoking at the time of screening. 2. be able to give written informed consent after being presented with an irb-approved informed consent document 3. be male or female of any race, between eighteen and sixty five years of age. 4. be in stable physical and mental health as judged by interview 5. be smoking 10 or more cigarettes per day for one or more years 6. have an expired co reading of ≥10 parts/million prior to beginning study 7. test non-pregnant and use adequate birth control (female only). all female subjects will have a urine pregnancy test performed prior to the first dose of study medication. 8. be able to comply with protocol requirements and be likely to complete all study treatments. 9. live within 50 miles of the study site exclusion criteria: 1. have current dependence, defined by dsm iv criteria, on any psychoactive substance other than nicotine, alcohol, or marijuana or physiological dependence on alcohol requiring medical detoxification. 2. have a history of significant hepatic, renal, endocrine, cardiac (i.e., arrhythmia requiring medication, angina pectoris, myocardial infarction,), stroke, seizure, neurological, non-drug-related psychiatric, gastrointestinal, pulmonary, hematologic or metabolic disorders. 3. have a history of adverse reaction/hypersensitivity to n-acetylcysteine. 4. have any significant active medical or psychiatric illness (e.g. schizophrenia, suicidal/homicidal ideation within the past 30 days) which might inhibit their ability to complete the study or might be complicated by administration of nac. 5. used carbamazepine or nitroglycerin within the last 14 days or any other medication felt to be hazardous if taken with nac 6. have a current or past history of asthma and/or the occasional or daily use of albuterol or other beta-agonist inhalers. 7. females pregnant or breast-feeding 8. have any medical history or condition considered by the investigator(s) to place the subjects at increased risk. 9. not fail to actively meet the inclusion criteria at the time of screening. 10. have a history of childhood or adult seizures of any cause. 11. be currently taking any medications (i.e., beta-blockers, stimulant medications) that might affect heart rate or skin conductance

Keywords: nicotine n-acetylcysteine smoking reduction
efficacy of loperamide for c. difficile colitis and other diarrheal diseases associated with antibiotic therapy

Conditions: Antibiotic-Associated Diarrhea; Clostridium Difficile

Summary: to determine whether symptomatic treatment of the diarrhea in cdad reduces morbidity and mortality of this serious nosocomial infection in patients who have antibiotic-associated diarrhea. both c. diff positive and negative patients will be included.

colitis due to clostridium difficile has been increasingly recognized as a serious nosocomial problem. recommended therapy is with metronidazole, 500 mg four times daily for 10 days. about 80% of patients respond to this therapy. however, the response may be be delayed, in which case debilitation due to diarrhea progresses. the 20% who do not respond tend to be sicker to start, and debilitation due to diarrhea is a severe problem. in reviewing the medical literature, we discovered that the earliest papers on c. difficile colitis emphasized symptomatic therapy with 'lomotil' (diphenoxylate with atropine). treatment to suppress the diarrhea fell out of favor in the late 1970's because of the theoretical consideration that it was better to expel than to retain the bacterial toxins. however, the patients who are affected by c. difficile colitis are increasingly elderly and debilitated, and suffer substantial morbidity from the diarrhea. we have shown that the 90-day associated mortality is \>20%. loperamide is a standard treatment for diarrhea, and is available over the counter under the name, imodium. based on a few anecdotal reports, this drug is regarded as contraindicated in patients whose diarrheal disease is bacterial. but it is used widely, and generally without any diagnosis being established. we now propose to administer loperamide or placebo to patients with cdad in order to determine whether the antidiarrheal drug reduces morbidity associated with the infection. we will monitor our patients closely both to observe potential benefits and/or adverse events. in the addendum, we propose to include patients who have antibiotic-associated diarrheal disease that is not due to c. difficile. there are many patients who have antibiotic-associated diarrheal disease who test negative for c. difficile. we believe that these patient may benefit from loperamide treatment as well.

Eligibility criteria:
inclusion criteria: * patients with diarrheal stools considered to be antibiotic associated exclusion criteria: * inability of sign consent * patient with other known gastrointestinal disease * patients receiving tube feeding or fecal incontinence prior to receiving antibiotics

Keywords: antibiotic associated diarrhea clostridium difficile loperamide
intensity-modulated radiation therapy in treating patients with stage i, stage ii, stage iii, or stage iv prostate cancer

Conditions: Prostate Cancer

Summary: rationale: radiation therapy uses high-energy x-rays to kill tumor cells. using scintigraphy to plan specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. purpose: this phase i/ii trial is studying the side effects and best way to give intensity-modulated radiation therapy and to see how well it works in treating patients with stage i, stage ii, stage iii, or stage iv prostate cancer.

objectives: * to assess the feasibility of radioimmunoguided intensity-modulated radiotherapy (imrt) for stage i-iv prostate cancer. * to determine the toxicity and tolerance of this regimen in these patients. * to determine the tumor response based on physical examination and serial measurements of the serum prostate-specific antigen (psa) levels in these patients. * to determine the outcome of patients treated on this study with radioimmunoguided imrt compared to 2 control groups of patients treated at mayo scottsdale clinic (msc). outline: patients undergo radioimmunoguided intensity-modulated radiotherapy once daily, 5 days a week for 8½ weeks. beginning the last week of radiotherapy, some patients receive leuprolide acetate intramuscularly every 3-4 months or goserelin subcutaneously every 3 months for 6 months, 12 months, or until disease progression. after completion of study treatment, patients are followed every 3-4 months for 1 year, every 6 months for 4 years and annually thereafter

Eligibility criteria:
disease characteristics: * pathologically confirmed prostate cancer * stage i-iv disease (t1-4, n0-1, m0) * no evidence of distant metastases (m0) on physical examination or bone scan patient characteristics: * ecog performance status 0-2 * hemoglobin ≥ 10.0 g/dl * wbc ≥ 3,000/mcl * platelet count ≥ 90,000/mm * ast \< 2 times the upper limit of normal * no allergy to leuprolide acetate or goserelin prior concurrent therapy: * not specified

Keywords: stage i prostate cancer stage ii prostate cancer stage iii prostate cancer stage iv prostate cancer
prophylactic selective lateral neck dissection in patients with papillary thyroid carcinoma

Conditions: Thyroid Neoplasm; Lymphatic Metastasis

Summary: the purpose of this study is to prospectively analyze the incidence of occult lateral neck metastasis (lnm) and to elucidate the factors that predict lnm in papillary thyroid carcinoma (ptc) with central neck metastasis (cnm) by performing prophylactic selective lateral neck dissection (snd).

the lymphatic drainage pattern of the thyroid is uniform and consistent, and therefore, metastatic patterns are relatively predictable. initial nodal metastasis in ptc usually occurs in the paratracheal and pretracheal nodes in level vi of the central compartment of the ipsilateral neck and spreads to the lateral cervical lymph nodes. macroscopic skip metastases to the lateral compartment of the neck in the absence of central disease are uncommon.

Eligibility criteria:
inclusion criteria: * papillary thyroid carcinoma with central neck metastasis * no evidence of lateral neck metastasis as determined by high-resolution neck ultrasonography and computed tomography exclusion criteria: * history of previous thyroid operation * isthmic thyroid lesion

Keywords: papillary thyroid carcinoma with neck metastasis neck dissection
effects of an oxalate containing product on dentinal hypersensitivity with dental prophylaxis

Conditions: Dentin Sensitivity

Summary: this study will assess sensitivity during a dental prophylaxis with or without the use of a potassium oxalate salt solution.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * sign an informed consent form and be given a copy * be in good general health as determined by the investigator/designee * agree to delay any elective dentistry, and to report any dentistry received during the course of the study * agree to not participate in any other oral care study for the duration of this study * agree to return for scheduled visits and follow all study procedures * have at least one tooth with a schiff sensitivity score of at least 1 in response to air challenge and a yeaple probe score of 10-40 in response to tactile challenge. exclusion criteria: * severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession * active treatment for periodontitis * any diseases or conditions that might interfere with the subject safely completing the study * inability to undergo study procedures * fixed orthodontic appliances
tbr-760 in adult patients with non-functioning pituitary adenomas

Conditions: Non-Functional Pituitary Adenoma; Pituitary Tumor, Nonfunctioning

Summary: this is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, efficacy, pk, and pd of the chimeric dopamine-somatostatin receptor agonist, tbr-760, in adult patients with nfpa over 52 weeks.

this is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, efficacy, pk, and pd of the chimeric dopamine-somatostatin receptor agonist, tbr-760, in adult patients with nfpa over 52 weeks. approximately 150 patients will be enrolled.

Eligibility criteria:
key inclusion criteria: * confirmed diagnosis of nfpa (defined as lack of clinical and biochemical evidence of adenohypophyseal hormone excess), and be status-post one tss with a nfpa remnant of ≥ 10mm (maximum diameter) * study subjects must be capable of giving informed consent and reading and signing the informed consent form after the nature of the study has been fully explained by the investigator or investigator designee * study subject must be willing and able to complete all study assessments and procedures and to communicate effectively with the investigator and site staff. key exclusion criteria: * has undergone more than one tss, or had tss \<6 months prior to screening, or is anticipated to require tss within 6 months of screening * has undergone radiation therapy to the head for any reason, or is already planned to have or anticipated to require radiation therapy during the study period; * has any contraindications to magnetic resonance imaging including allergy or intolerance to gadolinium or gadolinium-based contrast; * in the opinion of the investigator, the patient is unable to meet the requirements of the study.
feasibility open label study evaluating the use of process-instructed self neuro-modulation (prism) for post-traumatic stress disorder

Conditions: Post-traumatic Stress Disorder

Summary: this is a single-arm, open-label feasibility study. a maximum of 15 participants will be enrolled. all participants will undergo a novel neurofeedback intervention, targeting down-regulation of deep limbic structures, specifically the amygdalae. participants will complete 12 neurofeedback sessions delivered twice weekly over 6 consecutive weeks. the intervention will be delivered via the prism platform.


Eligibility criteria:
inclusion criteria: * adults ages 18-65 years * able to provide signed informed consent * any gender * diagnosis of ptsd as established by dsm-v * 1 to 15 years since index trauma * taking a stable dose of ssri antidepressants for at least 3 months or un-medicated for at least 2 months * normal or corrected-to-normal vision * normal or corrected-to-normal hearing * no intention of changing medication or psychotherapy for the duration of the study at the time of recruitment exclusion criteria: * concurrent substance abuse * use of any prescribed benzodiazepine * lifetime bipolar disorder, psychotic disorder, autism, mental retardation. comorbid mood and anxiety disorders will be permitted if they are not the primary focus of clinical attention * active suicidality within past year, or history of suicide attempt in past 2 years * any history of severe past drug dependence (i.e., a focus of clinical attention or a cause of substantial social or occupational difficulty) * any unstable medical or neurological condition * any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury \[tbi\] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days) * any psychotropic medication other than a stable dose of selective serotonin reuptake inhibitors (ssris) * any change in accepted psychotropic medication within the past 2 months * recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based ptsd psychotherapy (cognitive processing therapy \[cpt\], prolonged exposure \[pe\], eye movement -desensitization and reprocessing \[emdr\]); continuation of established maintenance supportive therapy will be permitted * significant hearing loss or severe sensory impairment * enrollment in another research study testing an experimental, clinical, or behavioral intervention intended to affect symptoms initiated within the last 2 months, or intended enrollment within the next 2.5 months
accelerating motor recovering in patients with sma syndrome after glioma surgery by using nrtms

Conditions: Motor Cortex; Lesion; Glioma; Supplementary Motor Area Syndrome

Summary: the goal of this randomized clinical controlled trial is to learn about whether neuro-navigation repetitive transcranial magnetic stimulation (nrtms) was useful to accelerate the recovery in patients with sma syndrome after glioma resection. the main questions aim to answer: * question 1: whether the nrtms was useful to accelerate the recovery of motor function back to the preoperative status in participants with sma syndrome after glioma resection. * question 2: whether the nrtms was useful to improve postoperative motor function in participants with sma syndrome after glioma resection. participants will continue to receive nrtms treatment or nrtms sham-treatment for 7 times on the 8th day after glioma resection to determine whether the tms was helpful for exercise rehabilitation. the investigator will evaluate the effects of nrtms treatment through the ratio of recovery of motor function and the time that was from the participants suffering sma syndrome to totally recover the motor function to the status of motor function in pre-operation.

this study will use the 8-coil (magstem, england, no.4150) and sham 8-coil (magstem, england) the criteria of enrolled patients are： a. inclusion time: from april 01 2023 to march 31 2025 (including the current month); b. inpatients in neurosurgery oncology wards of beijing tiantan hospital; c. right-handed, age: 25-55 years old, tumor located in sma, no previous treatment history of nervous system disease; d. the patient received wake-up surgery and applied direct cortical electrical stimulation during the operation to determine the location of the motor area; e. postoperative pathology was low grade glioma; f. can accept nrtms rehabilitation treatment. the excluding criteria are: a. the tumor grows across the midline to the opposite side; b. when collecting rs-fmri data, head movement exceeds 1mm and head deflection exceeds 1 °; c. the patient did not have sma syndrome after operation; d. vulnerable or special groups and protective measures, such as pregnant women.

Eligibility criteria:
inclusion criteria: * inpatients in neurosurgery oncology wards of beijing tiantan hospital * right-handed, age: 25-55 years old * tumor located in supplementary motor area * no previous treatment history of central nervous system disease * the patient received awaken craniotomy * pathological diagnosis is low grade glioma * volunteer to accept nrtms treatment exclusion criteria: * the tumor grows across the midline to the opposite side * regarding rs-fmri data, head movement exceeds 1mm and head deflection exceeds 1 ° * the patient did not have sma syndrome after operation * vulnerable or special groups and protective measures, such as pregnant women

Keywords: human motor recovery transcranial magnetic stimulation